Milan, Italy – December 23, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Financing Supports Clinical Development of Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease
Milan, Italy – November 20, 2015 – Newron Pharmaceuticals S
Milan, November 13, 2015 – Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron
Meiji Seika Pharma Co., Ltd. (Headquarter: Tokyo, Japan, President: Daikichiro Kobayashi, “Meiji”) announces that it has initiated Phase II/III confirmatory and Phase III long-
Milan, Italy, Sept. 30, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, and
Milan, Italy – September 15, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a research and development company focused on novel central nervous system (CNS) and pain
Milan, Italy – July 14, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, today
Milan, Italy – June 25, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces that it has received
Germany is the first country in which Xadago® is available as an add-on to levodopa alone and in combination with other PD medications
Milan – May 15, 2015 – Zambon S.p.A., an
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.